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Abstract. Heparins' unfractionated and low molecular weight, act primarily by their scav-
enging of thrombin (s-type heparins). via the feedback effect on factor vIII this has a sec-
ondary effect on prothrombin conversion in the intrinsic pathway (activated partial throm-boplastin time). The anti-Xa action of a heparin will not significantly inhibit prothrombin
conversion, except in the case of ultra low molecular weight heparins (p-type heparins) thathave no significant antithrombin activity. These P-type heparins need, therefore, be given athigh doses to have an antithrombotic effect. In platelet-rich plasma heparins retard platelet
activation by lowering thrombin levels. Activated platelets neutralize up to 0.5 U/ml of
unfractionated heparin, but low molecular weight heparin is much less affected.
All existing evidence, be it clinical, phar-
macological, or biochemical, indicates that
there is essentially only one efficacious way
to prevent and treat thrombosis, i.e., by de-
creasing the amount of thrombin. It is of
minor importance what the mechanism be-
hind the decrease is. It can be the inhibition
of thrombin formation, as in oral anticoagu-
lation, as well as the acceleration of throm-
bin breakdown, as in heparin therapy. As a
counterexample one can offer prevention of
thrombosis by aspirin Il]. Indeed, this sug-
gests that inhibition of thrombin is not the
only possible approach and that there is a
place for platelet inhibition. It should not go
unnoticed, however, that aspirin, although
the best available platelet inhibitor, is about
one third as effective as good anticoagula-
tron. Also, although everybody thinks in
terms of cyclooxygenase inhibition, it has
not been proven that this is the way by which
aspirin acts. We do not even exclude the pos-
sibility that aspirin acts via the inhibition of
platelet-mediated thrombin generation.
Admitting the importance of thrombin
does not, at this stage, automatically imply
that blood coagulation in the sense ofthe for-
mation of a fibrin clot is an essential part of
thrombus formation. The similarity between
a venous thrombus and a clot in a test tube
has sufficiently confused the field for the
time being. It should be recognized that
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thrombin has multiple actions on other clot-
ting factors, on platelets, and on endothelial
cells. A clot is simply the effect of the pres-
ence of thrombin under conditions of low or
absent flow. In flowing blood, thrombin may
still cause a thrombus, without the appear-
ance of frbrin being too obvious.
Stressing the role of thrombin does not
automatically mean that the anti-Xa action
should be negligibtc. The only known role of
factor Xa is to activate prothrombin. If fac-
tor Xa can be adequately inhibited, as in oral
anticoagulation, then this inhibition will
somewhat contribute to a lower prothrom-
bin conversion and hence to the inhibition of
thrombin formation. The question how far
heparins inhibit prothrombin conversion by
inhibiting factor Xa is a different issue that
will be addressed later. It will be clear that
insight in the mode of action of heparin
requires insight in the mechanism of throm-
bin formation. So we will first discuss throm-
bin formation.
Mechanism of Thrombin Formation
Core of the Mechanism
The main chain of proteolytic activations
induced by tissue thromboplastin in blood is
(in this and subsequent reaction schemes,
the arrow represents proteolytic activation
and not chemical conversion, square brack-
ets indicate enzymatically active complexes,
p1t : prekallikrein; TF : tissue factor; PL :
phospholipid, Roman numerals indicate the
coagulation factors):
V I I + X + I I
For intrinsic coagulation the main chain
of activations is:
P K + X I I + X I + I X + X + I I
All the nonactivated clotting factors par-
ticipating in these chains are proenzymes of
serine proteases, the activated enzymes con-
sequently are serine proteases. In free
aqueous solution, these proteolytic activa-
tions can be obtained, but they are acceler-
ated up to 100,000-fold, however' by the
presence of a negatively charged phospho-
lipid surface and specific protein cofactors'
To illustrate this mechanism we will take
the activation of prothrombin as an exam-
ple. Factor X. is capable to generate throm-
bin from prothrombin in free solution, but
only in a very ineffective mechanism [2-4]'
Paphadjopoulos and Hanahan [5] were the
first who observed that an active prothrom-
binase exists only in preparations that con-
tain the three components X", Vu, and phos-
pholipid. (The question of factor V activa-
tion will be discussed later.) Hemker et al' [6]
showed that the generation of prothrom-
binase activity can be described as the re-
versible formation of a complex of factors,
Xu and V, Ca2* and phospholipid. In a se-
ries of very elegant experiments Rosi'ng et
al. [7] showed that phospholipid diminishes
the K* for prothrombin conversion (a typi-
cal change would be from 3'000 to 30 rM),
whereas factor V. increases the turnover
number (k.u1) about 1,000-fold.
In 1967 Hemker and Kahn [8] found that
the factor X activating enzyme consists of
factors VIII. and IXu and phospholipid,
forming a complex completely analogous to
the prothrombinase complex. Later, van
Dieijen et al. [9] showed that in this complex
the kinetic effects of phospholipid (on K-)
and factor VIII' (on I(.u,) were similar to
those of phospholipid and factor Vu in the
prothrombinase complex. Apart from their
kinetic effect on k"u1, factors Vu and VIII"
also serve to better bind their respective en-
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zymes (factors X" and IXu) to phospholipid
l l 0 ,  l r l .
The available data, mainly from the
group of Nemerson [2] indicate clearly that
factor VII and tissue thromboplastin form a
complex that is again comparable to pro-
thrombinase. We can summarize the reac-
tions ofthe classical coagulation pathways as
follows:
Extrinsic pathway:
IVII, TF, PLI + [X, Va, PL] -+ II
Intrinsic pathway:
PK -+ XII + XI + [IX, VIIIa, PL] +
[X, Va, PL] + II
In the classical view, contact fabtors anc
antihemophilic factors form the intrinsic
pathway of thrombin formation, and the im-
portance of the role of the contact factors is
derived from the recognized importance of
the antihemophilic factors. The activating
action of factor VII on factor IX invalidates
this argument. The f,rrst indications that the
action of the antihemophilic factors VIII and
IX is not confined to the coagulation path-
way started by the contact factors were ob-
tained by Biggs and Nossel [3]. Josso and
Prou-Wartelle Ia] were the first to postulate
that factor VII can activate factor IX, so that
the antihemophilic factors play a role in
thromboplastin-triggered coagulation. This
means that factor X can be activated either
directly by factor VII and tissue thrombo-
plastin or indirectly by factor IX, (together
with factor VIIIa) that, in its turn, has been
activated by factor VII. It is easy to see that
the function of this pathway will anyhow be
dependent upon the amount of thromboplas-
tin available. The contribution of the direct,
one-step action of factor VII. on factor Xu
formation will be constant in time and
roughly proportional to the concentration of
thromboplastin. The contribution via the
pathway
VII --+ IX + X
will be small at the beginning of the reaction,
but will increase proportionally with time as
the factor X activating enzyme (i.e. factor
IX") builds up. The reinforcement loop con-
stituted by the antihemophilic factors was
called the Josso loop after its discoverer. As
has been demonstrated by Ma Xi [15] it will
gain in importance when clotting is started
by increasingly smaller amounts of thrombo-
plastin.
The early observations on the intercon-
nections between the extrinsic and the in-
trinsic pathway did not get the attention they
deserved until Osterud and Rappaport [16]
drew attention to the fact that the factor VII-
thromboplastin complex is capable of acti-
vating factor IX in a partially purifred sys-
tem. Later, Ztr and Nemerson [17], Jesty
and Silverberg [8] and Marlar and Griffrn
[19] established this pathway without any
reasonable doubt.
With the recognition of the Josso loop,
the ancient contradiction between the clini-
cal importance of the antihemophilic factors
(VIII and IX) and the relatively poor impor-
tance of the contact factors disappears. This
means that tissue factor becomes the only
important trigger of coagulation, as long as
no foreign surfaces tart to play a role.
Feedback Activation
It is essential for the correct function of
the hemostatic mechanism that thrombin
formation be precisely controlled. The
strong flow at the site ofa wound, generated
by the blood pressure, makes that thrombin
that would be slowly formed, even in mas-
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thrombin-activating protein C (see below).
This means that besides feedback activation,
feedback inhibition also plays an essential
role in the coagulation mechanism.
Both factor VIII and factor V have to be
activated before they can play their role as aprotein cofactor to the clotting enzymes.
Thrombin is the enzyme that brings about
these activations [20-24].
tered in the platelets is roughly 200/o f the
amount present in the plasma [29]. Throm_
bin, that causes the release reaction, will also
acrivate the released factor V. It has been
shown that this activation rather than the
release reaction itself is the rate_limiting fac_
tor for the generation of factor V activity
from triggered platelets [29J. The concentra_
tion of factor V in platelet_poor plasma is
about 25 nMwhereas that of its partner, fac_
tor X, is around 200 nM. This may lead one
to think that the contribution of platelet fac_
tor V may be important in vivo. The aggre_gation of platelets at sites where the hemo_
static mechanism is active will cause a fur_
ther increase in the platelet factor V_plasma
factor V ratio. Still parients with a ,torun"pool deficiency that are unable to release fa-c_
tor V from their platelets do not have an
rmportant hemorrhagic diathesis [30]. It
seems that only patients lacking factor V in
both platelets and plasma do show a hemor_
rhagic syndrome [31]. This may be explained
by the generally recognized factthatthe nor_
mal level of any clotting factor represents a
large functional excess. As a rule, the level of
any clotting factor must drop signifrcantly
below 200lo before a decrease of the clottine
function becomes apparent.
_ 
A second procoagulant function ofplate_
lets, induced by thrombin together with col_
lagen, is the platelet .flip_flop' reaction dis_
covered by Bevers et al. [32]. This reaction
consists of a transbilayer movement of the
procoagulant, negatively charged phospho-
lipids (primarily phosphatidylserin-) that as
a rule are to be found almost exclusivelv at
the inner face of the cell membrane. In the
presence of collagen and thrombin, platelets
p.roduce this procoagulant phospholipid out_
side the cell, without the cell being dis_
rupted. The precise molecular mechanism of
It has been described that in a human svs-
tem factor X" can activate factor VIII t251.
but recently the importance of this phenom_
enon in clotting plasma has been questioned
on good grounds [26].
At this moment it is established beyond
any reasonable doubt that activation of the
factors V and VIII is obligatory for their rak-
ing part in the coagulation mechanism.
From the work of Hurlet_Birk Jensen et al_
[27], it may be concluded that the activation
offactors V and VIII does occur in vivo dur_
ing the time course of normal hemostasis.
Among the proteins released by platelets
upon triggering with thrombin are factor V
and heparin-neutralizing proleins (platelet
factor 4). The amount of factor V'seques_
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this reaction is not yet clear. Anyhow, plate-
lets thus activated offer large amounts of
binding sites for the factors IXa, VIIIa, Xu,
and Vu at their outer surface, so that pro-
thrombinase and the factor X activating en-
zyme can readily form there. One patient
(Mrs. Scott, USA) has been described [33] in
whom this mechanism is defective: she suf-
fers from a mild hemorrhagic diathesis con-
sequently known as Scott syndrome.
It has been reported that collagen-acti-
vated platelets can start coagulation via a
factor XI dependent mechanism and that
adenosine diphosphate activation of plate-
lets triggers coagulation via factor XII [34].
These frndings remain to be confirmed. The
recent observation that platelets release a
potent inhibitor of factor XIa, so that factor
IX activation by factor XIa hardly proceeds
in the presence of activated platelets [35],
makes one doubt the importance of contact
activation for in vivo thrombin generation.
The current view on the starting mecha-
nism of coagulation is based on the observa-
tion that the proenzyme factor VII has a
nonnegligible enzymatic activity [36-38].
Once adsorbed onto tissue thromboplastin,
the activity of factor VII is enhanced, so as to
become sufficiently important to start the
clotting process. It has been observed, how-
ever, that there exists a more active form of
factor VII, the two-chain factor VII.. This
form can be generated from the one-chain
form in a number of different ways. Altman
and Hemker [39] showed, as early as 1967,
that the contact activation mechanism can
enhance factor VII activity in vitro. The cold
activation of factor VII, involving kallikrein
and different other proteins, has been well
established. It has also been described that
factor VII can be activated by factors IX"
and Xu [40,  4 l ] .
Feedback Inactivation
There are two important mechanisms
that depend on the previous activation of a
clotting factor and that lead to eventual inhi-
bition of thrombin formation: (1) protein C
and protein S dependent inactivation ofthe
factors Vu and VIII. and (2) the extrinsic
pathway inhibitor mechanism.
Downstream of a lesion in the vessel wall,
there will be a region with intact endothe-
lium. Thrombomodulin [42] occurs at the
surface of intact endothelial cells. Thrombin
binds with high aflinity to this molecule and
undergoes a modulation of its specificity. It
is no longer capable ofany action on the clot-
ting factors I, V, VIII, or XIII. Instead, it
becomes capable of activating protein C.
Protein C [a3] is a vitamin K dependent pro-
serine prot,,ase that, once it is activated by
the thrombin-thrombomodulin complex, be-
comes a potent inactivator of factors V. and
VIII,. 'Ihis makes that the survival time of
factor Va and factor VIIIa must be very
short in a region lined by intact endothelium
where thrombin has passed. The action of
activated protein C is markedly enhanced by
another vitamin K dependent factor: pro-
tein S.
The extrinsic pathway inhibitor is a circu-
lating plasma protein that also is adsorbed
on the endothelial wall. It has the capacity to
bind to activated factor X and to form a
complex that is a strong inhibitor of the
thromboplastin-factor VII. complex. This
mechanism makes that tissue factor induced
factor X activation will stop as soon as a suf-
ficient amount of factor X" has been pro-
duced. The details of the kinetic conse-
quences of this behavior remain to be inves-
tigated. For full details on the extrinsic path-
way inhibitor, the reader is referred to the
paper by Rapaport [44].
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Mode of Action of Heparins
The inactivation of the active serine pro-
teases of blood coagulation is a physiologr-
cally important mechanism. Antithrombin
III (ATIII) is the main plasma protein re-
sponsible for this action 145-47l.Its impor-
tance is readily deduced from the fact that a
500/o defrciency state implies a major risk of
thrombosis. Also (near) complete deficiency
is never seen, probably because it is a lethal
mutation. Apart from ATIII, coagulation
proteases are to some extent inactivated by
o2-macroglobulin and other antiproteases
such as o,t-antitrypsin [see ref. 48 for a re-
viewl. We determined that ATIII in clotting
plasma is responsible for the inhibition of
640/o of the thrombin formed, o,2-rnacro-
globulin for 23o/o, and remaining inhibitors
for 13 o/0.
Among the antiproteases ATIII is ex-
tremely important because of the fact that its
activity can be enhanced by hepanns which
makes it the lever on which this important
family of antithrombotic drugs acts. Heparin
cofactor II will not contribute to thrombin
inactivation under normal circumstances
[a9]. In spite of its name, it will neither be
active in the presence oftherapeutic heparin
concentrations. It starts to play a role, how-
ever, when drugs like dermatan sulfate or
pentosan polysulfate are present in the plas-
ma. It is interesting to note that those drugs
that act with heparin cofactor II only cannot
be overdosed which might be the major
cause of their allegedly low hemorrhagic ac-
tivity. The plasma, concentration of pro-
thrombin is -21tM, that of ATIII -3, and
that of heparin cofactor II - I pM. This
makes that activated ATIII can kill all the
thrombin that might ever be formed, but
that in the case ofheparin cofactor II activa-
tion always half of the thrombin goes un-
harmed.
As we have discussed before, thrombin
will enhance its own formation by activat-
ing factors V and VIII as well as platelets.
Any inhibition of thrombin formation and
any reaction that inactivates thrombin will
interfere with this positive feedback. The
intricate pathways of coagulation inhibi-
tion by heparin are mainly determined by
these feeedback effects, as we will now dis-
cuss.
Extrinsic System
Biochemical studies on isolated clotting
factors have advanced our knowledge ofthe
coagulation system enormously. One of the
major insights that we have obtained in this
way is that the complete system is so com-
plex thar it will be impossible to predict the
effect of e.g., heparin by extrapolating from
our knowledge of purified systems. The
study of the physiological chemistry of the
'isolated organ' called plasma is a much
more complicated matter than the study of
purified clotting factors. If we understand.
what happens in a patient receiving heparin,
then there is no alternative, however. One of
the problems encountered is that in plasma
the effect of heparin on thrombin decay may
be accompanied by an effect on prothrombin
activation. The observation that the ATIII-
heparin complex, especially in the case of
low molecular weight heparins, has a definite
capacity to inactivate added factor Xa has
led to the assumption that factor Xa inhibi-
tion in plasma under the influence of hepa-
rin might lead to inhibition of prothrombin
conversion. This is not to be taken for
granted, however, because it has been shown
that the prothrombinase complex is immune
to antithrombin action [50, 5l].
Heparins: Mode of Action 8 7
In order to distinguish between this effect
and thrombin decay and a possible effect on
thrombin generation, we developed a meth-
od to dissect them mathematically [52]. The
rationale behind this method is the follow-
ing: We know that the velocity of thrombin
breakdown is linearly proportional to the
thrombin concentration. The proportional-
ity constant is ka"". It varies between - I
min-r for normal plasma without additions
to -6 min-lwhen 0.1 U/ml is present in the
plasma. The variation is in good approxima-
tion l inear with the heparin concentration.
This makes that every heparin can be as-
signed a specific decay constant defined as
the increase of h." per microgram per mill-
liliter of heparin in normal plasma. Once k6..
is known, it is in principle easy to obtain the
time course of prothrombin conversion from
the time course of thrombin formation. At
any point of the thrombin generation curye,
we can determine the net rate of thrombin
formation (v"*o). We can also calculate the
velocity of thrombin breakdown (vd.. : ko".
X thrombin concentration). The sum of'
both velocities is the velocity of prothrom-
bin conversion. In practise there is the com-
plication of the generation of the amidoly.ti-
cally active thrombin-a2-macroglobulin
complex. We refer to the original literature
to explain how this problem has been solved
t521.
Applying this method to a study of tire
effects of heparins on thrombin generation
in plasma, we found that, in the extrinsic sys-
tem, all heparins act primarily on thrombin
breakdown and hardly have an effect on pro-
thrombin conversion [53, 54]. That is to say
that there is an effect, but in our system (and
in real life probably) it can hardly be ob-
served because at the concentrations that are
necessary to demonstrate, e.9., 500/o inhibi-
tion, thrombin inactivation is so high that no
thrombin can be measured in the system
anyhow. This is equally true for unfraction-
ated low molecular weight heparins [55].
Only heparins that do not affect thrombin
breakdown, such as Choay's pentasaccha-
ride, can be added at such high concentra-
tions that important prothrombinase inhibi-
tion is observable [55, 56].
This seems to be in contradiction to the
fact that low molecular weight heparins will
preferentially inactivate factor Xa rather
than thrombin, but it is not, when two part-
ners of the tripartite prothrombinase com-
plex are present at a f,rxed concentration,
then the prothrombinase concentration will
depend upon the concentration of the third
one. It will show saturation kinetics. That is
to say that. if the varying concentration is
increased, the prothrombinase activity will
hyperbolically approach the limit set by the
concentration of the rate-limiting partner [6](see figure l). Given a plasma concentration
of factor V of -20 nM and one of factor X of
-200 nM, factor Va will more readily be
rate limiting than factor Xa. Under these
circumstances, it is logical that variations
in factor Xa concentrations, such as are
brought about by increasing factor Xa break-
down with low molecular weight heparins,
will not translate immediately in propor-
tional decreases of prothrombinase activity
(fre. l).
Apart from the fact that factor Xa evi-
dently is not rate limiting for prothrom-
binase formation, the comprehension of the
importance of the inactivation of factor Xa
by low molecular weight heparins is also
hampered by technical problems. The decay
of thrombin and factor Xa, as it is usually
measured, is only remotely related to the
actual decay in plasma. It has been found
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Factor  Va:  03  nM
P h o s p h o L i p  d  1  p / V
Fig. l. Prothrombinase activity as a function of
factor Xa concentration. The situation at the peak of
prothrombinase activity in clotting plasma is mim-
icked. Factor Va is rate limiting. Its concentration is
sufliciently high to explain the observed rate of pro-
thrombin conversion (200 nM/nin\. The observed
concentrations of factor Xa (> 10 n41) represent a
large excess.
that the Ca2* concentration has an important
influence on the speciflc decay constants
found and that this influence is not the same
for every type ofheparin. Also there are defi-
nite species differences, so that bovine fac-
tors in human blood need not necessarily
give relevant information.
Recent research work from our group
[Wielders and Bendetowicz, unpublished
data] has confirmed our earlier notion of the
existence of two types of heparin. The S-type
heparins in clotting plasma enhance pri-
marily the inactivation of thrombin, whereas
the P-type heparins have no or hardly an
activity towards this enzyme. Within the S
group, the specific decay constants towards
thrombin vary relatively little (<4-fold) if
they are calculated on the basis of the
amount of heparin with an high aflinity for
ATIII. It was surprising to see that the ICzs
(the IC56 could for obvious reasons not be
measured, see above) did not lrary very
much between all heparins tested (< 5-
fold).
The picture that seems to develop upon
investigation of a large series (> 30) of dif-
ferent heparin fractions is that: (l) the
amount of ATIII-binding material is roughly
proportional to the molecular weight,
(2) there is a group of very low molecular
weight heparins that does not significantly
affect thrombin breakdown in plasma (P
heparins); (3) the specific decay constant for
thrombins of the S heparins (i.e., most hepa-
rins in clinical use, inclusively unfraction-
ated heparin) varies only in fourfold range,
without clear dependence upon the molecu-
lar weight, if expressed in terms of hieh-
affinity material, and (4) the influence of
both P- and S-type heparins on prothrom-
binase is approximately equal and again in-
dependent of molecular weight, if expressed
in terms of high-affinity material. In S-type
heparins this activity is diffrcult to estimate
as it is overshadowed by the antithrombin
activity.
It is curious to see that the feedback acti-
vation of factor V by thrombin does not
affect the prothrombinase formation in the
extrinsic system to any significant extent un-
der our conditions. This is not a new obser-
vation because it reflects the well-known fact
that the prothrombin time is hardly affected
by heparin.
Intrinsic System
Contrary to the extrinsic system, the in-
trinsic system does show lag times of throm-
bin formation that are significantly pro-
longed by heparin. This is the equivalent of
the activated partial thromboplastin time
being sensitive to heparin.
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We have shown that the length of the lag
time is determined by the time necessary for
so much thrombin to form so much acti-
vated factor VIII that tenase activity can
start [53]. This means that there must be a
small but defrnite thrombin formation dur-
ing the lag phase. This we could indeed dem-
onstrate (frg. 2). In the presence ofheparins,
the concentration of the thrombin available
during the lag time decreases, so that it will
take longer for sufficient factor VIIIa to be
activated.
It has been shown that the gOneration of
factor IXa is not inhibited by heparin [57].
Factor IXa, although remarkably stable
when no heparin is present, is subject to
heparin-induced inactivation. If there is a
long lag time, factor IXa is 'incubated' dur-
ing that time with ATIII heparin and pro-
portionally inactivated. The amount of fac-
tor IXa that is left when finally enough fac-
tor VIIIa is generated to end the lag time,
determines the amount of prothrombinase
that eventually forms. The action of unfrac-
tionated heparin on thrombin, therefore,
will be the main factor responsible for the
sensitivity of the activated partial thrombo-
plastin time to heparin, whereas its action
on factor IXa will contribute to the magni-
tude of the heparin effect on the total
amount of thrombin formed. It must be
noted, however, that all inhibitions high in
the system will eventually translate in less
thrombin, so that it will inhibit any throm-
bin-mediated effect. A good example is the
effect of pentasaccharide in the intrinsic sys-
tem. Pentasaccharide will have no signifi-
cant direct effect on thrombin or factor IXa
breakdown. Because of its effect on factor
Xa, it will cause low ambient concentrations
of thrombin during the lag time and, there-
fore, prolong it [53].
Fig. 2. Thrombin formation during the lag time of
intrinsic coagulation. Kaolin and phospholipid are
added at zero time together with Ca2t. The three
curves represent the same experiment. It is clear that
traces of thrombin are formed during the first 2 min
that tend to escape observation, unless special precau-
tions are taken.
Platelet-Rich Plasma
When clotting is started in platelet-rich
plasma, the platelets are not yet activated at
the start ofthe reaction, and the system can
be regarded as platelet-poor plasma in which
unactivated platelets are suspended. In this
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'platelet-poor plasma' traces of thrombin
form in the usual way. This thrombin therr,
apart from activating factors V and VIII,
also activates the platelets. At normal plate-
let concentrations (3.108/ml), thrombin can
bring about full platelet activation. For the
clotting system three aspects ofplatelet acti-
vation are of importance: release of factor V
release ofplatelet factor 4,and generation of
procoagulant phospholipid surface. The lat-
ter process consists of shedding of vesicles
that exhibit phosphatidylserine at the out-
side and of flip-flop of the platelet mem-
brane [32]. Factor V that is released is acti-
vated by the thrombin present. It has been
shown that this activation is slow as com-
pared with the release reaction [29].
Because of the presentation of factor Va
and ofprocoagulant phospholipid, the con-
ditions for prothrombin conversion become
much more favorable, and a burst of throm-
bin occurs. We could demonstrate that espe-
cially the availability of phospholipids is re-
sponsible for the thrombin burst, although
platelet factor V does contribute [58].
It is an impressive phenomenon to see
that the peak of that burst is hardly affected
by the presence of up to 0.4 U/ml of unfrac-
tionated heparin! The explanation of this
phenomenon is that the heparin-neutralizing
material that is shedded by the platelets takes
care of the heparin present, so that once
thrombin formation has really started, it goes
on unhampered. This makes that the only
effect of unfractionated heparin on thrombin
generation in platelet-rich plasma is prolon-
gation of the lag time. Low molecular weight
heparins on the contrary are capable ofinhib-
iting the thrombin peak even in the presence
of activated platelets. This may be one of the
main differences between unfracionated and
low molecular weight heparins [58].
The inactivation of large amounts of un-
fractionated heparin by platelet activation
products has an important practical conse-
quence. Unless special. precautions are tak-
en, platelets will almost always activate to
some extent during venipuncture. This will
cause measurements of unfractionated hepa-
rin to be severely affected by the quality of
the venipuncture. Also one may ask wether
preferential inactivation of certain heparin
fractions can occur. If, e.g. the antithrombin
activity would more readily neutralize the
anti-Xa activity, this might disturb pharma-
cokinetic determinations of these two activi-
tres.
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